Clinical Trial Update: Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy results for ARQ 501 in adults with leiomyosarcoma; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• ARQ 501

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cancer | Phase 2 | Status: COMPLETED